Blood · 1997 · 478 citations · 19 references
Life SciencesCell BiologyHematologyCell PhysiologyRegenerative MedicineStem Cell BiologyBone Marrow MicroenvironmentBone Marrow PhysiologyHematopoietic DevelopmentHematopoietic DifferentiationHematopoietic Stem Cell BiologyHematopoietic Stem CellsAdult Hematopoietic Stem CellsCord Blood CellsCord Blood EngraftmentCord Blood HematologyPeripheral Blood Stem CellsUmbilical Cord Blood Stem Cells
We have previously reported the development of in vivo functional assays for primitive human hematopoietic cells based on their ability to repopulate the bone marrow (BM) of severe combined immunodeficient (SCID) and nonobese diabetic/SCID (NOD/SCID) mice following intravenous transplantation. Accumulated data from gene marking and cell purification experiments indicate that the engrafting cells (defined as SCID-repopulating cells or SRC) are biologically distinct from and more primitive than most cells that can be assayed in vitro. Here we demonstrate through limiting dilution analysis that the NOD/SCID xenotransplant model provides a quantitative assay for SRC. Using this assay, the frequency of SRC in cord blood (CB) was found to be 1 in 9.3 x 10(5) cells. This was significantly higher than the frequency of 1 SRC in 3.0 x 10(6) adult BM cells or 1 in 6.0 x 10(6) mobilized peripheral blood (PB) cells from normal donors. Mice transplanted with limiting numbers of SRC were engrafted with both lymphoid and multilineage myeloid human cells. This functional assay is currently the only available method for quantitative analysis of human hematopoietic cells with repopulating capacity. Both CB and mobilized PB are increasingly being used as alternative sources of hematopoietic stem cells in allogeneic transplantation. Thus, the findings reported here will have important clinical as well as biologic implications.
19
H.J. Sutherland, Peter M. Lansdorp, D Henkelman et al. · Proceedings of the National Academy of Sciences · 1990 · 678 citations